Abigail Beaney

Argenx's Vyvgart first gained approval by the FDA for generalised myasthenia gravis (gMG) in 2021.

Otsuka’s Voyxact was granted accelerated approval from the FDA in November 2025 based on nine-month data.

At the American Diabetes Association (ADA) conference 2026, Roche, Lilly and others presented data.

If the Phase III trials of the oral GLP-1RA are successful, AstraZeneca is set to join a fast-growing market.

Gilead and MSD will be filing the data from the Phase III trials of the once-weekly HIV pill to regulatory authorities.

While Sanofi’s study of riliprubart in CIPD has been terminated, another study will continue.

On a panel at NHS Confed Expo, experts discussed the UK and US pricing agreement and how clinical trials will improve access to innovative medicines.

Based on this data and data from two other Phase III trials, Takeda will file for the approval of zasocitinib in PsA.

Lilly presented Phase I data from the type II JAK inhibitor, showing good efficacy and safety.

Several studies of GLP-1RAs in oncology were presented at ASCO 2026, showing their potential in both prevention and treatment.